UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CARDIOVASCULAR & METABOLIC

Medpace

M

Medpace

Cardiovascular & MetabolicCincinnati, United States
Visit Website

About Medpace

Medpace is a scientifically driven contract research organisation (CRO) recognised for its full-service clinical development model and deep therapeutic expertise. Founded in 1992 and headquartered in Cincinnati, Ohio, the company has built its reputation on a differentiated approach: keeping scientific leadership in-house rather than outsourcing clinical operations, which allows for tighter integration across study design, regulatory strategy, and data management.

The company serves a global client base spanning large pharmaceutical companies, biotechnology firms, and medical device manufacturers. Medpace operates across more than 40 countries and maintains a network of dedicated Phase I clinical pharmacology units alongside global laboratory services through its MedLabs subsidiary. This integrated laboratory capability, rare among CROs, supports bioanalytical testing, central laboratory functions, and specialised assay development without reliance on third parties.

Medpace has developed particular depth in oncology, cardiology, and metabolic disease, areas where regulatory complexity and protocol sophistication demand experienced clinical teams. The company also carries notable strength in rare and orphan diseases, working with sponsors navigating accelerated pathways and adaptive trial designs. Its scientific advisory structure brings therapeutic area specialists directly into study oversight, a model the company has maintained as a core differentiator since its founding.

Listed on the Nasdaq exchange under the ticker MEDP, Medpace has posted consistent growth and is widely regarded as one of the more profitable and operationally focused mid-to-large CROs in the sector. Its employee-ownership culture and low reliance on acquisitions distinguish it from larger conglomerate CROs that have grown primarily through consolidation.

Further information is available at medpace.com.

Similar Companies

More in Cardiovascular & Metabolic

W

Worldwide Clinical Trials

Operating across more than 60 countries, Worldwide Clinical Trials is a full-service contract research organisation built around a single discipline: clinical development. Founded in 1986, the company has spent nearly four decades focusing exclusively on Phase I through Phase IV studies, giving it a depth of therapeutic and regulatory expertise that generalist CROs rarely match. The organisation is particularly well regarded for its work in central nervous system research, where it operates dedicated CNS units with specialist investigators and patient populations. Alongside CNS, Worldwide Clinical Trials carries strong capabilities in cardiovascular, metabolic, and rare disease development, areas where patient recruitment complexity and protocol design demand experienced hands. Its Phase I infrastructure includes purpose-built clinical pharmacology units that support first-in-human studies, bioavailability and bioequivalence work, and early proof-of-concept programmes. This early-phase foundation connects seamlessly into its late-phase trial management, allowing sponsors to maintain a single CRO relationship from initial dosing through to regulatory submission. Worldwide Clinical Trials works primarily with mid-size and emerging biopharmaceutical companies, positioning itself as a committed partner rather than a high-volume processor. That focus has earned it a reputation for therapeutic expertise and operational flexibility, qualities that sponsors managing complex or novel compounds tend to prioritise. Headquarters are in Wayne, Pennsylvania, with a global network of offices and clinical sites spanning North America, Europe, and beyond. Further information is available at worldwide.com.

View profile
P

Pfizer

Pfizer is one of the world's largest research-based biopharmaceutical companies, with a history stretching back to 1849 and a presence in more than 125 countries. Headquartered in New York City, the company is listed on the New York Stock Exchange under the ticker PFE and is a constituent of the Dow Jones Industrial Average, reflecting its standing as a cornerstone of global healthcare. Core Therapy Areas and Pipeline Pfizer's portfolio spans oncology, internal medicine, vaccines, rare diseases, and hospital-acquired infections. The company's oncology business, built in part through the acquisition of Wyeth and later Medivation, includes targeted therapies that have become widely prescribed across breast, kidney, and lung cancers. Its vaccines division is among the largest globally, and the company's partnership with BioNTech to develop an mRNA-based vaccine during the COVID-19 pandemic brought its manufacturing and distribution capabilities to worldwide attention. The rare disease unit, operating under the Pfizer Rare Disease brand, addresses conditions with limited treatment options across haematology, neurology, and metabolic disorders. Global Scale and Manufacturing Pfizer operates one of the most extensive pharmaceutical manufacturing networks in the world, with dozens of production sites across North America, Europe, and Asia. Research and development investment consistently ranks among the highest in the industry, supporting a pipeline that at any given time includes hundreds of programmes at varying stages. The company's internal medicine portfolio includes long-established brands in cardiovascular disease, pain, and infectious disease alongside newer treatments for conditions such as atopic dermatitis. Pfizer has pursued a sustained acquisition strategy over decades, with landmark transactions including Warner-Lambert, Pharmacia, Wyeth, Hospira, and Array BioPharma, each expanding its therapeutic reach or manufacturing capacity. In 2022 the company acquired Global Blood Therapeutics and Arena Pharmaceuticals, and in 2023 completed the acquisition of Seagen, significantly strengthening its oncology pipeline with antibody-drug conjugate technologies. Further information is available at pfizer.com.

View profile
M

Moderna

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna is a clinical-stage biotechnology company listed on the Nasdaq (ticker: MRNA) that has built its entire operation around a single scientific bet: that messenger RNA can be harnessed as a programmable medicine. Rather than developing one drug at a time, the company operates as an mRNA platform business, using the same underlying technology to generate candidates across vaccines, oncology, rare disease and cardiovascular indications. The mRNA Platform and Pipeline More than fifteen years of continuous mRNA research underpin Moderna's proprietary mRNA Design Studio, a discovery and development environment that allows scientists to design, iterate and optimise mRNA sequences with a speed that conventional small-molecule or biologics programmes cannot match. The platform has already produced two approved products: Spikevax, its COVID-19 vaccine authorised in multiple markets worldwide, and mRESVIA, an mRNA-based vaccine for respiratory syncytial virus approved by the US FDA in 2024 for adults aged 60 and over. A broad pipeline sits behind these approvals, including an investigational seasonal influenza vaccine (mRNA-1010), a personalised cancer vaccine programme developed in collaboration with Merck that uses individualised mRNA sequences to target tumour-specific neoantigens, and candidates targeting cytomegalovirus, latent HIV and rare metabolic disorders. Global Operations and Commercial Scale Moderna maintains country-specific commercial and regulatory operations across North America, Europe and Asia Pacific, with established presences in the United States, Canada, the United Kingdom, France, Germany, Italy, the Netherlands, Spain, Switzerland, Poland, Australia, Japan, South Korea, Hong Kong, Taiwan and Singapore. The company has received substantial non-dilutive funding through longstanding partnerships with US government agencies including BARDA and DARPA, which supported its early platform work. Investor relations, healthcare professional resources, supplier programmes and a clinical trials portal are all maintained as distinct operational functions, consistent with Moderna's scale as a multi-market biopharmaceutical organisation. Further information is available at modernatx.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy